95%Confidence
0Views
FDASource
2026-03-03Date
Summary
Third Fresenius Kabi Compounding recall for vancomycin sterility issues confirms systemic quality problems. This could impact hospital infection control protocols and increase liability for healthcare providers.
Actionable: Suspend all Fresenius Kabi Compounding purchases and conduct emergency audits of remaining sterile products.
AI Confidence: 95%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productvancomycin HCl, 1.5 grams, 1.5 grams added to 500 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now